

Keith E Stockerl-Goldstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857697/publications.pdf>

Version: 2024-02-01

196
papers

10,754
citations

57681

46
h-index

38517

99
g-index

198
all docs

198
docs citations

198
times ranked

16076
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. <i>Blood Advances</i> , 2022, 6, 1991-2000.	2.5	11
2	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2022, 139, 1177-1183.	0.6	41
3	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
4	COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. <i>American Journal of Medicine</i> , 2022, 135, S49-S52.	0.6	5
5	What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders?. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
6	COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. <i>Acta Haematologica</i> , 2022, 145, 244-256.	0.7	7
7	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2
8	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabm1375.	5.8	49
9	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
10	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
11	Letemovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 510.e1-510.e9.	0.6	20
12	A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. <i>American Heart Journal</i> , 2021, 232, 137-145.	1.2	4
13	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449.	0.6	2
14	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	1.3	2
15	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3043-3046.	0.6	1
16	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , 2021, 32, 787-800.	0.6	240
17	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
18	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	1.5	4

#	ARTICLE	IF	CITATIONS
19	How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis. <i>JACC: CardioOncology</i> , 2021, 3, 590-593.	1.7	3
20	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	2.8	32
21	Financial Toxicity Among Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4027-4027.	0.6	2
22	Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. <i>Blood</i> , 2021, 138, 2849-2849.	0.6	0
23	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1188-1190.	1.3	1
24	Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. <i>British Journal of Haematology</i> , 2020, 188, 501-510.	1.2	36
25	Cardio-Oncology Education and Training. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2267-2281.	1.2	41
26	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
27	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	7.7	83
28	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
29	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
30	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. <i>Transplant International</i> , 2020, 33, 1089-1098.	0.8	1
31	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	1.7	16
32	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	0.8	12
33	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
34	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 19-20.	0.6	27
35	Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. <i>Blood</i> , 2020, 136, 28-30.	0.6	5
36	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8502-8502.	0.8	32

#	ARTICLE	IF	CITATIONS
37	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	2.3	138
38	A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. Blood, 2020, 136, 31-32.	0.6	0
39	Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. JACC Basic To Translational Science, 2019, 4, 438-448.	1.9	38
40	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 285-289.	0.2	17
41	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e588-e593.	0.2	6
42	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783.	3.2	14
43	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	2.5	89
44	GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. Future Oncology, 2019, 15, 3555-3563.	1.1	18
45	Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991.	1.3	42
46	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 140-140.	0.6	22
47	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	2.3	113
48	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701.	0.6	0
49	The Role of IRE1 α : Overexpression of IRE1 α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1 α Expression Is Predictive of Therapy Resistance. Blood, 2019, 134, 4351-4351.	0.6	1
50	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830.	1.2	32
51	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 11-20.	2.3	142
52	Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 687-693.	2.0	5
53	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer, 2018, 124, 816-825.	2.0	44
54	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer, 2018, 124, 4342-4349.	2.0	29

#	ARTICLE	IF	CITATIONS
55	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	1.2	30
56	Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. <i>Leukemia Research</i> , 2018, 72, 86-91.	0.4	7
57	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364.	0.2	4
58	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. <i>Blood</i> , 2018, 132, 5666-5666.	0.6	1
59	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 2021-2021.	0.6	1
60	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4463-4463.	0.6	0
61	Disparities in Healthcare Resource Utilization for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4793-4793.	0.6	1
62	A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2146-2146.	0.6	0
63	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 5627-5627.	0.6	1
64	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3439-3439.	0.6	0
65	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 241-243.	0.6	0
66	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017, 123, 2025-2034.	2.0	48
67	A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, e542-e542.	2.8	41
68	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1282-1289.	2.0	5
69	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
70	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. <i>Blood</i> , 2017, 129, 2680-2692.	0.6	66
71	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1072-1077.	2.0	39
72	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , 2017, 6, 2814-2821.	1.3	21

#	ARTICLE	IF	CITATIONS
73	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2065-2069.	2.0	19
74	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , 2017, 130, 816-816.	0.6	7
75	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. <i>Transfusion</i> , 2016, 56, 2331-2335.	0.8	7
76	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 389-400.	2.3	62
77	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2535-2540.	0.6	11
78	Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy. <i>Pharmacotherapy</i> , 2016, 36, 1087-1094.	1.2	7
79	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.4	31
80	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	13.9	663
81	Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2155-2158.	2.0	8
82	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 728-730.	0.6	14
83	A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 453-455.	0.6	0
84	Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2142-2142.	0.6	34
85	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. <i>Blood</i> , 2016, 128, 3563-3563.	0.6	2
86	Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety. <i>Blood</i> , 2016, 128, 4497-4497.	0.6	2
87	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. <i>Blood</i> , 2016, 128, 5611-5611.	0.6	1
88	Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2133-2133.	0.6	0
89	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2349-2349.	0.6	0
90	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 1106-1110.	2.0	19

#	ARTICLE	IF	CITATIONS
91	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348.	0.8	94
92	High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1075-1082.	1.3	36
93	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1425-1430.	2.0	12
94	Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 353-360.	0.5	52
95	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2643-2649.	0.6	47
96	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. <i>Diabetes</i> , 2015, 64, 2969-2977.	0.3	50
97	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
98	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1153-1154.	2.0	14
99	A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2100-2105.	2.0	25
100	Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure. <i>Bone Marrow Transplantation</i> , 2015, 50, 134-136.	1.3	6
101	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3098-3098.	0.6	1
102	A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 516-516.	0.6	3
103	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015, 126, 689-689.	0.6	1
104	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	2.3	55
105	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3144-3144.	0.6	0
106	Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 1853-1853.	0.6	0
107	Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3196-3196.	0.6	0
108	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. <i>International Journal of Hematology</i> , 2014, 99, 272-278.	0.7	32

#	ARTICLE	IF	CITATIONS
109	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
110	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 337-341.	0.6	12
111	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	5.1	113
112	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 487-492.	2.0	9
113	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. <i>American Journal of Hematology</i> , 2014, 89, E103-8.	2.0	15
114	Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. <i>Haematologica</i> , 2014, 99, e162-e164.	1.7	39
115	Geriatric Assessment in Older Adults with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 1286-1286.	0.6	2
116	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2557-2557.	0.6	1
117	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	0.6	11
118	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. <i>Blood</i> , 2014, 124, 555-555.	0.6	24
119	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , 2014, 124, 1931-1931.	0.6	4
120	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	0.6	1
121	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 5696-5696.	0.6	0
122	Impact of Remission Status on Outcomes in AML Patients ≥ 60 Years of Age after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1263-1263.	0.6	0
123	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5292-5292.	0.6	0
124	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4731-4731.	0.6	0
125	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	0.6	0
126	A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. <i>Leukemia</i> , 2013, 27, 725-728.	3.3	38

#	ARTICLE	IF	CITATIONS
127	Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. <i>Oncologist</i> , 2013, 18, 1074-1079.	1.9	36
128	Multiple Myeloma, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 11-17.	2.3	63
129	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5492-5492.	0.6	3
130	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. <i>Blood</i> , 2013, 122, 3931-3931.	0.6	0
131	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. <i>Blood</i> , 2013, 122, 2816-2816.	0.6	0
132	Commentary. <i>Clinical Chemistry</i> , 2012, 58, 675-675.	1.5	0
133	Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2012, 47, 516-521.	1.3	10
134	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1211-1219.	2.3	38
135	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2012, 119, 3917-3924.	0.6	347
136	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood</i> , 2012, 120, 1801-1809.	0.6	393
137	Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 125-133.	2.0	46
138	Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 280-288.	2.0	81
139	Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. <i>Transplant Infectious Disease</i> , 2012, 14, 259-267.	0.7	23
140	Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.. <i>Blood</i> , 2012, 120, 2965-2965.	0.6	1
141	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. <i>Blood</i> , 2012, 120, 331-331.	0.6	24
142	Genome-Wide Copy Number Analyses Correlated with Outcomes in Untreated Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 3991-3991.	0.6	0
143	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92
144	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1828-1833.	0.6	104

#	ARTICLE	IF	CITATIONS
145	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. <i>American Journal of Hematology</i> , 2011, 86, 796-800.	2.0	39
146	Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 631-631.	0.6	6
147	Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1146-1183.	2.3	58
148	Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 3633-3633.	0.6	0
149	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 3616-3616.	0.6	1
150	Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. <i>Blood</i> , 2011, 118, 809-809.	0.6	0
151	Phase I Study of Cladribine (2-chlorodeoxyadenosine), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML. <i>Blood</i> , 2011, 118, 3609-3609.	0.6	0
152	High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1830-1830.	0.6	0
153	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML. <i>Blood</i> , 2010, 116, 1060-1060.	0.6	10
154	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection. <i>Blood</i> , 2010, 116, 1063-1063.	0.6	1
155	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Blood</i> , 2010, 116, 823-823.	0.6	1
156	Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 862-862.	0.6	5
157	Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: A Single Center's 12-Year Experience. <i>Blood</i> , 2010, 116, 2360-2360.	0.6	0
158	A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 4512-4512.	0.6	6
159	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. <i>Blood</i> , 2010, 116, 680-680.	0.6	0
160	A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2009, 84, 560-564.	2.0	51
161	Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. <i>American Journal of Hematology</i> , 2009, 84, 733-737.	2.0	42
162	Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. <i>Bone Marrow Transplantation</i> , 2009, 43, 793-800.	1.3	26

#	ARTICLE	IF	CITATIONS
163	Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. <i>Bone Marrow Transplantation</i> , 2009, 44, 13-17.	1.3	19
164	A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and SÅ©zary Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 982-990.	2.0	108
165	Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 908-942.	2.3	112
166	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3417-3417.	0.6	1
167	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. <i>Blood</i> , 2009, 114, 787-787.	0.6	5
168	Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. <i>Blood</i> , 2009, 114, 3335-3335.	0.6	0
169	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056.	2.0	319
170	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. <i>Blood</i> , 2008, 112, 1944-1944.	0.6	8
171	Multiple Myeloma Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 118.	2.3	43
172	High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 703-711.	2.0	13
173	Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. <i>Blood</i> , 2005, 105, 2300-2306.	0.6	57
174	CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. <i>Experimental Hematology</i> , 2005, 33, 279-285.	0.2	43
175	Protective Conditioning for Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2005, 353, 1321-1331.	13.9	319
176	Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 47-55.	2.0	115
177	Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2004, 103, 777-783.	0.6	192
178	A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 276-282.	2.0	3
179	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	0.6	382
180	Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. <i>Blood</i> , 2002, 99, 1442-1448.	0.6	132

#	ARTICLE	IF	CITATIONS
181	High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 294-301.	2.0	75
182	Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 552-560.	2.0	35
183	A decade of progress in allogeneic hematopoietic cell transplantation: 1990â€“2000. <i>Advances in Cancer Research</i> , 2001, 81, 1-59.	1.9	1
184	Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. <i>Cancer</i> , 2001, 91, 2205-2213.	2.0	8
185	Effect of Oral Glutamine Supplementation During Bone Marrow Transplantation. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 61-66.	1.3	105
186	Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 254-261.	2.0	86
187	Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 262-271.	2.0	152
188	Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 387-394.	2.0	47
189	High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 496-505.	2.0	13
190	Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 506-512.	2.0	65
191	Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 621-627.	2.0	136
192	Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 58-69.	2.0	12
193	High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 352-358.	2.0	57
194	Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 555-562.	2.0	14
195	Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myelomaâ€”A Feasibility Study. <i>Blood</i> , 1999, 93, 2411-2419.	0.6	385
196	Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 299-305.	2.0	60